Pediapharm Inc. (CVE:PDP), a biopharma penny stock, moved up after Health Canada approved its drug for Seasonal Allergic Rhinitis
Sean Mason | July 21, 2016 | SmallCapPower
Allergy relief made more than a few biopharma penny stock shareholders feel better Thursday, while drill results weighed on a gold junior. Here’s some small stocks making big moves on Thursday, July 21, 2016 (as of 4 pm EST):
Biopharma penny stock Pediapharm Inc. (CVE:PDP) jumped 10% to $0.27 on Thursday after announcing that Health Canada has approved rupatadine for the relief of the symptoms associated with Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis and Chronic Spontaneous Urticaria in patients two years of age and older.
As well, shares of NuLegacy Gold Corporation (CVE:NUG) slipped 11% to $0.275 as the gold explorer released assay results for the first 10 holes of the 40+ hole (10,000 meter) 2016 exploration program on its 100% owned Iceberg oxide gold deposit in Nevada. Results included 0.52 g/t gold over 35.1 metres.
Arctic Star Exploration Corp. (CVE:ADD), meanwhile, reported that it has acquired 40,831 hectares of mineral claims in the Western Athabasca Basin of Saskatchewan, which will be known as the Diamond Dunes Project, in consideration for $25,000 cash plus one million Arctic Star shares. Arctic Star Exploration stock moved up 60% to $0.04.
Finally, Dynasty Metals & Mining Inc. (TSE:DMM) shares surged 33% to $0.20 after the miner announced that an agreement has been reached between Elipe, SA, Dynasty’s Ecuadorian subsidiary, and the Zaruma gold mine workers such that, effective immediately, these miners return to work at Zaruma and continue mining activities.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source.
